ASCO 2025
ASCO 2025
Advertisement
Yelena Janjigian, MDGastric Cancer | June 16, 2025
Dr. Janjigian shares why MATTERHORN was picked for the plenary and how its findings build on past studies in G/GEJ cancer.
View More
Filippo Pietrantonio, MDGastric Cancer | June 10, 2025
Dr. Pietrantonio discusses how the benefits of T-DXd can potentially reshape the current treatment algorithm.
Benjamin Weinberg, MD, FACPColorectal Cancer | June 10, 2025
Dr. Weinberg explains why combining transcriptomic & genomic features can offer an advantage over prior biomarker ...
Vincent Picozzi, MDPancreatic Cancer | June 10, 2025
Dr. Picozzi details PANOVA-3, where TTFields with chemo showed significant survival gains in advanced pancreatic cancer.
Emily MenendezGIST | June 10, 2025
Long-term results support the durable efficacy of binimetinib plus imatinib in treatment-naïve advanced GIST.
Lauren Dembeck, PhDEsophageal Cancer | June 9, 2025
In the first-line HER2+ G/GEJ cancer, combinations of DV, toripalimab, and chemo produce high ORRs and promising early PFS.
Jeanne Tie, MD, MBChBASCO 2025 | June 6, 2025
Professor Tie discusses DYNAMIC-III, a trial using ctDNA to guide chemo escalation in stage III colon cancer.
Zev Wainberg, MD, MScGastric Cancer | June 6, 2025
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Christopher Lieu, MDColorectal Cancer | June 5, 2025
Dr. Lieu highlights the randomized trial that looked at atezo with the standard of care for stage III dMMR colon cancer.
Lauren Dembeck, PhDColorectal Cancer | June 5, 2025
The findings are considered practice changing and support EC+mFOLFOX6 as a new SOC for BRAF V600E-mutant mCRC.
Lauren Dembeck, PhDColorectal Cancer | June 5, 2025
The ATOMIC trial showed that adding atezo to mFOLFOX6 significantly improves DFS in stage III colon cancer and dMMR.
Ronan Kelly, MDEsophageal Cancer | June 3, 2025
Dr. Kelly discusses the first overall survival results from CheckMate 577 and how they compare to previous DFS results.
Richard Kim, MDBile Duct Cancer | June 3, 2025
Dr. Kim discusses survival outcomes of zanidatamab compared to chemotherapy in patients with previously treated HER2+ BTC.
Richard S. Finn, MDLiver Cancer | June 3, 2025
Dr. Finn discusses the follow-up of LEAP-002 and its clinical implications despite not meeting the primary end points.
Devalingam Mahalingam, PhDPancreatic Cancer | June 2, 2025
Dr. Mahalingam shares preliminary results from the randomized phase 2 study of elraglusib with gemcitabine/nab-paclitaxel.
Lauren Dembeck, PhDPancreatic Cancer | June 2, 2025
A post hoc analysis of the NAPOLI 3 trial offers insight into prolonged survival in mPDAC.
Lauren Dembeck, PhDPancreatic Cancer | June 2, 2025
A therapy has shown a statistically significant OS benefit in patients with unresectable locally advanced pancreatic cancer.
Zachary BessettePancreatic Cancer | June 2, 2025
Results of CASSANDRA may alter the standard of care for patients with resectable PDAC.
Michele Reni, MDPancreatic Cancer | June 1, 2025
Dr. Reni breaks a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III PDAC.
Lauren Dembeck, PhDEsophageal Cancer | May 30, 2025
Adjuvant nivolumab provides durable long-term DFS benefit and shows an OS advantage in patients with resected EC/GEJC.
Advertisement
Advertisement
Latest News

June 16, 2025